Summary of Key Points from the Conference Call Company Overview - The company discussed its performance for 2025 and provided guidance for 2026, indicating a strong growth trajectory in various business segments, particularly in the chemical macromolecule and emerging business sectors [2][3][16]. Financial Performance - In 2025, the company achieved a revenue of 6.67 billion yuan, a year-on-year increase of 14.9%, aligning with the growth guidance of 13%-15% [3][16]. - The adjusted net profit for 2025 was 1.253 billion yuan, reflecting a growth of over 50% compared to 2024 [3][16]. - The gross profit margin for 2025 was stable at 42%, with a net profit margin of 17%, up by 0.6 percentage points [3][16]. Order Backlog and Growth - As of Q1 2026, the company had an order backlog of 1.385 billion USD, a 31.7% increase year-on-year, driven primarily by the macromolecule business [2][3][16]. - The fourth quarter of 2025 saw a significant increase in orders, marking the highest growth rate in five quarters, attributed to new business orders [2][20]. Business Segment Performance Small Molecule Business - Revenue for the small molecule segment in 2025 was 4.735 billion yuan, a 3.6% increase, with a gross margin of 46.8% [4][6]. - The company is involved in five GLP-1 clinical projects, with two in late-stage development [6][20]. Emerging Business - The emerging business segment generated 1.929 billion yuan in revenue, a 57.3% increase, with a gross margin of 30.1%, up 8 percentage points from 2024 [4][6]. - Revenue from overseas markets in this segment grew by 240% [4][6]. Chemical Macromolecule Business - This segment saw a revenue increase of 123% to 1.028 billion yuan, with a backlog growth of 127.6% [4][6]. - The company is servicing 19 GLP-1 clinical projects, with eight in late-stage development [6][15]. Biopharmaceutical CDMO - The biopharmaceutical CDMO business nearly doubled its revenue to 294 million yuan, with a 55.6% increase in order backlog [9][10]. - The first ADC commercial workshop is expected to be delivered in Q2 2026 [10]. Capital Expenditure and Capacity Expansion - The company plans to invest 2.1 billion yuan in capital expenditures for 2026, with 70%-80% directed towards new business segments [2][19]. - The production capacity for solid-phase peptide synthesis is expected to expand to 69,000 liters by the end of 2026 [2][19]. Market Trends and Challenges - The company noted that the recent Middle East conflict has led to price increases in raw materials, but the overall impact on costs is manageable [17][18]. - There is a growing demand for new modalities in the CDMO market, particularly in conjugated drugs and peptides, indicating a positive outlook for future orders [21][22]. Outlook for 2026 - The company expects revenue growth of 19%-22% for 2026, with an additional 2-3 percentage points expected from constant currency adjustments [2][16]. - The gross margin for the emerging business is anticipated to improve further due to increased overseas revenue and enhanced delivery capabilities [18][22]. Conclusion - The company is well-positioned for continued growth across its various business segments, with a strong order backlog and strategic investments planned for capacity expansion and new business development [2][3][16][19].

Investment Rating - The investment rating for the company is "Buy" for both A and H shares [7]. Core Views - The company reported a revenue of 6.67 billion RMB for 2025, representing a year-over-year increase of 14.9% (16.8% at constant exchange rates), and a net profit attributable to shareholders of 1.13 billion RMB, up 19.4% year-over-year [1][2]. - The company expects a revenue growth of 19%-22% for the full year of 2026, supported by a strong order backlog of 1.385 billion USD, which is a 31.7% increase year-over-year [1]. - Emerging businesses, particularly in chemical and biological macromolecules, have shown rapid growth, with a revenue increase of 57.3% year-over-year in 2025 [3]. Summary by Sections Financial Performance - The company achieved a gross margin of 42.0% in 2025, a slight decrease of 0.4 percentage points year-over-year. The sales, management, and R&D expense ratios were 3.2%, 11.5%, and 8.9%, respectively, all showing a decrease year-over-year due to cost reduction initiatives [2]. - Operating cash flow improved to 1.408 billion RMB, reflecting a 12.2% year-over-year increase [2]. Emerging Business Growth - Revenue from emerging businesses reached 1.929 billion RMB, with international revenue increasing by over 240%. The segment's gross margin improved to 30.1%, up 8.5 percentage points year-over-year [3]. - Specific highlights include: - Chemical macromolecules revenue of 1.028 billion RMB, up 123.7% year-over-year, with a significant order backlog growth of 127.6% [3]. - Biological macromolecules revenue of 294 million RMB, up 95.8% year-over-year, with a 55.6% increase in order backlog [3]. Core Business Development - The small molecule CDMO segment generated 4.735 billion RMB in revenue, a 3.6% year-over-year increase, with 515 projects delivered in 2025 [4]. - The company anticipates 16 small molecule PPQ projects in 2026, indicating a robust pipeline for future growth [4]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders for 2026-2028 is adjusted to 1.42 billion RMB, 1.84 billion RMB, and 2.23 billion RMB, respectively, with increases of 8% and 13% compared to previous estimates [5]. - The company is valued at 37x PE for A shares and 29x PE for H shares for 2026, with target prices set at 145.61 RMB and 129.44 HKD, respectively [5].

Financial Overview - Total revenue for 2025 reached CNY 6.67 billion, a 14.9% increase from 2024 [74] - Adjusted net profit was CNY 1.25 billion, reflecting a 56.1% growth [12] - Gross profit margin stood at 42.0%, with an adjusted net profit margin of 18.8% [12] Business Segment Performance Small Molecule CDMO - Revenue from small molecule CDMO business was CNY 4.74 billion, a 3.6% increase year-on-year [19] - Gross margin for small molecule business was 46.8% [19] - The segment delivered 59 commercial projects and 515 clinical projects, including 70 Phase III projects [26] Emerging Business - Emerging business revenue surged to CNY 1.93 billion, a 57.3% increase [19] - International revenue from this segment exceeded CNY 850 million, growing over 240% [19] - Gross margin for emerging business improved to 30.1%, up 8.4 percentage points [19] Biologics CDMO - Revenue from biologics CDMO reached CNY 294 million, a 95.8% increase [41] - The segment executed 130 projects, including 5 BLA projects and 46 IND projects [41] Market Expansion - The company added over 300 new clients in 2025, enhancing its global market presence [20] - Revenue from multinational pharmaceutical companies was CNY 4.92 billion, accounting for 52% of total revenue [20] Future Outlook - Projected revenue growth for 2026 is estimated between 19% and 22% [70] - The company plans to invest approximately CNY 2.1 billion in capital expenditures to expand production capacity [70]

Core Viewpoint - Kailaiying (06821) has seen a stock price increase of over 3%, currently at 85.8 HKD, with a trading volume of 13.68 million HKD. The company reported a revenue of 4.63 billion CNY for the first three quarters of 2025, reflecting an 11.82% year-on-year increase, and a net profit of 800 million CNY, up 12.66% year-on-year. The company anticipates a significant increase in delivery scale in Q4 compared to Q3, projecting an overall revenue growth of 13%-15% for the year [1][1][1]. Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 4.63 billion CNY, which is an 11.82% increase year-on-year [1]. - The net profit attributable to shareholders was 800 million CNY, marking a 12.66% year-on-year increase [1]. - The basic earnings per share stood at 2.18 CNY [1]. Business Segments - The small molecule CDMO business, a cornerstone of Kailaiying, reported revenue that remained flat year-on-year, with a gross margin of 47.0%, down 1.9 percentage points [1]. - Emerging business segments showed strong growth, with a revenue increase of 71.9% year-on-year and a gross margin of 30.6%, up 10.6 percentage points [1]. - The revenue from the chemical macromolecule business grew by over 150% year-on-year [1]. Market Outlook - The company is actively expanding its market presence in emerging business areas such as peptides, oligonucleotides, and ADC, with new orders maintaining double-digit growth [1]. - The expansion of production capacity is expected to position emerging business segments as a core growth engine for the company [1].

Investment Rating - The investment rating for the company is "Outperform the Market" [5][3][20] Core Views - The company achieved steady growth in the first three quarters of 2025, with revenue reaching 4.63 billion yuan (+11.82%) and net profit attributable to shareholders at 800 million yuan (+12.66%) [1][6] - Emerging businesses are becoming the core growth engine, with a significant increase in revenue from new business areas, particularly in chemical macromolecules, which saw over 150% growth [2][3] - The company is expected to maintain rapid revenue growth throughout 2025, with projected revenues of 6.68 billion yuan, 7.53 billion yuan, and 8.29 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 15%, 13%, and 10% [3][4] Financial Performance Summary - For the first three quarters of 2025, the company reported quarterly revenues of 1.54 billion yuan, 1.65 billion yuan, and 1.44 billion yuan for Q1, Q2, and Q3 respectively, with Q2 showing the highest growth at +26.95% [1][6] - The operating cash flow improved to 1.144 billion yuan (+8.38%), indicating enhanced operational efficiency and effective cost control [2][12] - The gross margin for the small molecule CDMO business was 47.0% (-1.9pp), while the emerging business gross margin was 30.6% (+10.6pp) [2][3] Earnings Forecast - The company forecasts net profits of 1.14 billion yuan, 1.29 billion yuan, and 1.46 billion yuan for 2025, 2026, and 2027 respectively, with expected growth rates of 20%, 14%, and 14% [3][4] - The current price-to-earnings ratio (PE) is projected to be 29.8, 26.3, and 23.1 for the years 2025, 2026, and 2027 respectively [3][4]

Core Viewpoint - Huazhong Securities report indicates that Kailaiying achieved a net profit attributable to shareholders of 800 million yuan in the first three quarters of 2025, representing a year-on-year growth of 12.66%. However, the net profit for Q3 alone was 183 million yuan, showing a year-on-year decline of 13.46% [1] Financial Performance - In Q3 2025, the company's performance experienced slight fluctuations primarily due to the impact of order delivery schedules. It is expected that the delivery scale in Q4 will significantly exceed that of Q3 based on the distribution of pending orders from the second half of the year [1] - The company maintains its full-year performance guidance, projecting an annual revenue growth of 13%-15% [1] Order and Business Growth - In Q3 2025, the company signed new orders with double-digit growth, which has improved compared to the growth rate in the first half of the year. The new business segments, including chemical macromolecules and biological macromolecules, have shown strong growth in new orders [1] Capital Expenditure Plans - The company plans to increase its capital expenditure significantly, raising the expected amount for 2025 to 1.3-1.4 billion yuan, primarily focusing on emerging business areas. Capital expenditure is expected to further increase in 2026 [1] Profitability Outlook - Given that the current gross margin level of emerging businesses is relatively low, an increase in revenue share from these areas is anticipated to lower the overall gross margin of the company. Consequently, the profit forecasts for 2025-2027 have been revised downward [1] - The company maintains a "Buy" rating despite the adjustments to profit forecasts [1]

Group 1: Company Performance Overview - The company achieved double-digit growth in new orders for Q3, with an acceleration compared to the first half of the year [2] - The new business segments, including chemical and biological macromolecule businesses, are showing strong growth, indicating a positive revenue outlook for 2026 [2] Group 2: Capacity and Capital Expenditure - The capital expenditure for 2025 is projected to increase to approximately 1.3-1.4 billion, focusing on new business areas [3] - The small molecule business is experiencing tight capacity, particularly in Tianjin, while the Northeast facility is operating at normal utilization levels [3] - The company is expanding its capacity in the chemical macromolecule sector, with significant growth expected in the peptide and oligonucleotide businesses [3] Group 3: Profitability and Margins - The gross margin for new business segments reached 30.6% in the first three quarters of 2025, an increase of 10.6 percentage points year-on-year [4] - The domestic business revenue is expected to continue increasing, driven by a competitive domestic market and ongoing projects [5] - The company is implementing cost control measures to ensure that expense growth remains below revenue growth [6] Group 4: Market Trends and Future Outlook - The company anticipates a revenue growth of 13%-15% for the full year 2025, with increasing growth rates expected in 2026 and 2027 [4] - The domestic revenue share is expected to rise, supported by the increasing number of projects going overseas [5] - The company is focusing on enhancing its capabilities to capture more collaboration opportunities in the rapidly growing new molecule sector [4] Group 5: Competitive Positioning - The company’s core competencies lie in its delivery capabilities and investment in new technologies aimed at significantly reducing production costs [7] - The revenue structure of the chemical macromolecule business shows over 50% coming from peptide business, with a shift towards overseas markets expected [8]

Core Viewpoint - The company reported a revenue of 4.63 billion RMB for the first three quarters of 2025, reflecting a year-on-year increase of 11.82%, and a net profit attributable to shareholders of 800 million RMB, up 12.66% [1] Revenue Breakdown - The revenue from small molecule business remained stable, while emerging business revenue grew by 71.87% year-on-year, and revenue from large molecule chemistry increased by over 150% [1] - Revenue from large pharmaceutical companies was 2.053 billion RMB, a year-on-year increase of 1.98%, while revenue from small and medium-sized pharmaceutical companies reached 2.577 billion RMB, up 21.14% [1] Future Outlook - The company anticipates that the delivery scale in the fourth quarter will significantly exceed that of the third quarter, projecting an overall revenue growth of 13%-15% for the year [1]

Core Insights - The company reported a total revenue of 4.63 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 11.82% [1] - The revenue from emerging businesses increased by 71.87%, while the revenue from large molecule chemistry grew by over 150% [1] - The net profit attributable to shareholders reached 800 million yuan, marking a year-on-year increase of 12.66% [1] Revenue Breakdown - Revenue from large pharmaceutical companies amounted to 2.05 billion yuan, with a year-on-year growth of 1.98% [1] - Revenue from small and medium-sized pharmaceutical companies was 2.58 billion yuan, reflecting a year-on-year increase of 21.14% [1] Profitability Metrics - The overall gross profit margin for the company was 42.44% for the first three quarters of 2025 [1] - The gross profit margin for small molecule business was 46.99%, remaining stable year-on-year [1] - The gross profit margin for emerging businesses improved by 10.57 percentage points to 30.55%, driven by increased delivery scale and capacity utilization [1] Future Outlook - The company anticipates that the delivery scale in the fourth quarter will significantly exceed that of the third quarter [1] - The company expects an annual revenue growth of 13%-15% for the full year [1]

Core Viewpoint - Kailaiying (002821) reported a slight decline in Q3 revenue and net profit, but showed overall growth in the first three quarters of 2025, indicating resilience in emerging and large molecule businesses [1] Financial Performance - Q3 revenue was 1.442 billion yuan, a year-on-year decrease of 0.09% [1] - Q3 net profit was 183 million yuan, a year-on-year decrease of 13.46% [1] - Revenue for the first three quarters reached 4.63 billion yuan, a year-on-year increase of 11.82% [1] - Net profit for the first three quarters was 800 million yuan, a year-on-year increase of 12.66% [1] Business Segments - Revenue from small molecule business remained stable [1] - Revenue from emerging businesses grew by 71.87% year-on-year [1] - Revenue from large molecule business increased by over 150% year-on-year [1] - Revenue from large pharmaceutical companies was 2.053 billion yuan, a year-on-year increase of 1.98% [1] - Revenue from small and medium pharmaceutical companies was 2.577 billion yuan, a year-on-year increase of 21.14% [1] Future Outlook - The order distribution for the second half of the year indicates that Q4 delivery scale will significantly exceed that of Q3 [1] - The company expects annual revenue growth to achieve between 13% and 15% [1]